Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updat...

Full description

Bibliographic Details

Published in:	Blood cancer journal (New York) 2020-11, Vol.10 (11), p.111-111, Article 111
Main Authors:	Kaufman, Jonathan L, Dimopoulos, Meletios A, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather J, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Miles Prince, H, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J, Chari, Ajai, O'Rourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad Z, San-Miguel, Jesus
Format:	Article
Language:	eng
Subjects:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Chromosome Deletion Chromosomes, Human Cytogenetic Analysis Dexamethasone - administration & dosage Dexamethasone - adverse effects Disease-Free Survival Humans Immunotherapy Lenalidomide - administration & dosage Lenalidomide - adverse effects Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - mortality Recurrence Steroids Survival Rate Targeted cancer therapy Translocation, Genetic
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!